However, conventional predictive methods, encompassing tumour pathology, tumour staging systems, and PLD-1 expression levels, have proven ineffective in accurately predicting the response to antitumour immunotherapy (Squamous cell lung cancer). This evidence concerns the gene PLD1 and neoplasm.